Combination Study of SV-BR-1-GM With Retifanlimab

Clinical trial NCT03328026 · COMPLETED

Trial details

NCT number: NCT03328026
Sponsor: BriaCell Therapeutics Corporation
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Cancer Breast Neoplasm Metastatic Breast Cancer Breast Cancer Metastatic

Start date: 2018-03-16
Primary completion: 2026-03-24
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.